Clinical Trials

The ITN conducts clinical trials with the goal of achieving immune tolerance for patients. To see a list of ITN's clinical trials that are currently enrolling participants, please select a disease area: 

Allergy & Asthma          Autoimmune Disease          Transplantation         Type 1 Diabetes

To see all of ITN's active and completed studies, please visit For Researchers.

T1D Extended Study (T1DES)

Principal Investigator:
Linda DiMeglio, MD, MPH, Indiana University and Riley Hospital for Children, Indianapolis, IN

T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.

Learn more:

Allograft Tolerance Study (ALLTOL)

Principal Investigator:
Laurence Turka, MD, Massachusettes General Hospital, Boston, MA

ALLTOL is an observational clinical study to learn more about tolerance in organ transplantation.

Learn more:

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)

Principal Investigator:
James Markmann, MD, PhD, Massachusettes General Hospital, Boston, MA

OPTIMAL is a clinical trial that will be investigating immunosuppression withdrawal in liver transplant recipients.

Learn more:

Preserving Beta-Cell Function with Tocilizumab in New-Onset Type 1 Diabetes (EXTEND)

Principal Investigator:
Carla Greenbaum, MD, Benaroya Research Institute, Seattle, WA

Jane Buckner, MD, Benaroya Research Institute, Seattle, WA

EXTEND is a clinical research study that will test whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking the remaining beta cells and possibly extend the ability to naturally produce insulin in individuals recently diagnosed with type 1 diabetes.

Learn more: